Poxel SA (LTS:0RA2)
€ 0.1424 0 (0%) Market Cap: 7.53 Mil Enterprise Value: 52.36 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 8/100

Poxel SA New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Corporate Call Transcript

Jul 12, 2021 / 05:15PM GMT
Release Date Price: €6.37 (-3.19%)
Thomas Kuhn
Poxel S.A. - Co-Founder, CEO & Director

Thank you for joining us today. I'm Thomas Kuhn. I'm the CEO of Poxel.

You can see here, before we begin, our forward-looking statements. Forward-looking statements are subject to inherent risks and uncertainties beyond the company's control that could cause the company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. Further information can be found in our most recent regulatory filing.

Here, you can see the agenda for the call today. So I will give a brief introductions highlighting our strategy, then I will hand over to Marc Engelen. And to begin with, I'd like to thank very much Marc Engelen to participate to this call. Marc is the MD PhD pediatric neurologist from Amsterdam, specifically really being very close to this pathology, leukodystrophy, and is heading the Amsterdam leukodystrophy center. Then we'll hear from Ben Lenail. Ben will give his patient perspective. Ben is the co-founder and a Board member of ALD

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot